Crisugabalin

Crisugabalin
Legal status
Legal status	US: Investigational New Drug; Rx in China;
Identifiers
	IUPAC name 2-[(1S,2S,3R,6S,8S)-2-(aminomethyl)-2-tricyclo[4.2.1.03,8]nonanyl]acetic acid;
CAS Number	2209104-84-5 ;
PubChem CID	139300919;
DrugBank	DB19300;
ChemSpider	115009778;
UNII	Q3MK7E8686;
ChEMBL	ChEMBL5314958;
Chemical and physical data
Formula	C12H19NO2
Molar mass	209.289 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1C[C@@H]2[C@@H]3C[C@H]1C[C@@H]3[C@@]2(CC(=O)O)CN;
	InChI InChI=1S/C12H19NO2/c13-6-12(5-11(14)15)9-2-1-7-3-8(9)10(12)4-7/h7-10H,1-6,13H2,(H,14,15)/t7-,8-,9+,10-,12-/m0/s1; Key:WCEFMBSFXJUREW-LIJGXYGRSA-N;

Crisugabalin (HSK16149) is a selective GABA analog in development for the treatment of chronic pain. It has a wider therapeutic index than pregabalin, which has a similar mechanism of action. In China, it was approved in May 2024 for the treatment of diabetic peripheral neuropathic pain^[1] and approved in July 2024 for the treatment of postherpetic neuralgia.^[2] In the United States, it is in Phase III trials as of 2023.^[3]^[4] The drug can be administered with or without food.^[5]

Legal status

US: Investigational New Drug
Rx in China

CAS Number

2209104-84-5^Y

PubChem CID

139300919

DrugBank

DB19300

Quick facts Legal status, Identifiers ...

Close

[1]

[2]

[3]

[4]

[5]

Crisugabalin

See also

References

Related Articles

Legal status

Legal status	US: Investigational New Drug Rx in China
Identifiers
IUPAC name 2-[(1S,2S,3R,6S,8S)-2-(aminomethyl)-2-tricyclo[4.2.1.0^3,8]nonanyl]acetic acid
CAS Number	2209104-84-5^Y
PubChem CID	139300919
DrugBank	DB19300
ChemSpider	115009778
UNII	Q3MK7E8686
ChEMBL	ChEMBL5314958
Chemical and physical data
Formula	C₁₂H₁₉NO₂
Molar mass	209.289 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES C1C[C@@H]2[C@@H]3C[C@H]1C[C@@H]3[C@@]2(CC(=O)O)CN
InChI InChI=1S/C12H19NO2/c13-6-12(5-11(14)15)9-2-1-7-3-8(9)10(12)4-7/h7-10H,1-6,13H2,(H,14,15)/t7-,8-,9+,10-,12-/m0/s1 Key:WCEFMBSFXJUREW-LIJGXYGRSA-N